Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02429089 | Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck(CETLEE011) | Phase 1 | terminated | Apr 29, 2015 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Decided by the investigator due to the difficulties to recruit | Investigator |
| NCT04044651 | Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With… | Phase 2 / Phase 3 | withdrawn | Aug 5, 2019 | Shi Ming | Bristol-Myers Squibb company terminated this study | Sponsor / business decision |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | Phase 1 | terminated | Jul 20, 2010 | M.D. Anderson Cancer Center | Requested by PI during yearly Continuing Review | Other (stated, no rule matched) |
| NCT02487277 | PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma | Phase 2 | terminated | Jul 1, 2015 | Andrew Ko | Low accrual | Enrollment / accrual |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients… | Phase 2 | terminated | Jul 13, 2009 | Mayo Clinic | not stated | Not stated |
| NCT03321903 | EPR Tumor Oximetry With CE India Ink | — | terminated | Oct 26, 2017 | Philip Schaner | The research team is exploring device optimization | Other (stated, no rule matched) |
| NCT03692338 | INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or…(INTERVAL) | N/A | terminated | Oct 2, 2018 | Duke University | Poor accrual | Enrollment / accrual |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | Phase 1 | terminated | Sep 27, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | Phase 2 | withdrawn | Aug 1, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or… | Phase 1 | terminated | Oct 29, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular…(NUANCE) | Phase 1 | terminated | Dec 26, 2017 | University of Utah | PI decided to terminate due to low/slow accrual | Enrollment / accrual |
| NCT00582712 | An Initial Study of Lithium in Patients With Medullary Thyroid Cancer | Phase 2 | terminated | Dec 28, 2007 | University of Wisconsin, Madison | Budget/Funding | Funding |
| NCT00985946 | Study of Panobinostat in Patients With Neuroendocrine Tumors | Phase 2 | terminated | Sep 29, 2009 | University of Wisconsin, Madison | Study did not meet statistical requirements to continue. | Other (stated, no rule matched) |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | Phase 1 | terminated | Jan 13, 2014 | GlaxoSmithKline | The risk benefit in relapsed refractory SCLC does not favor continuation of the study | Other (stated, no rule matched) |
| NCT03433703 | Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following… | Phase 2 | terminated | Feb 14, 2018 | Eisai Inc. | Study recruitment was stopped due to difficulty in enrolling the targeted number of participants. | Enrollment / accrual |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab +…(ATTILA) | Phase 3 | withdrawn | Jan 22, 2019 | iOMEDICO AG | Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP… | Other (stated, no rule matched) |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT00975806 | Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy… | Phase 1 / Phase 2 | terminated | Sep 11, 2009 | Celgene | MTD determined sub-optimal as efficacious treatment for renal cell carcinoma. | Other (stated, no rule matched) |
| NCT01974284 | Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma | N/A | terminated | Nov 1, 2013 | Yale University | Lack of patient enrollment | Enrollment / accrual |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | Phase 2 | terminated | Jun 18, 2009 | National Cancer Institute (NCI) | Premature closure due to slow/insufficient accrual. | Enrollment / accrual |
| NCT00537511 | A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047… | Phase 1 / Phase 2 | terminated | Oct 1, 2007 | Celgene | This study was terminated for administrative reasons. | Other (stated, no rule matched) |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | Phase 2 | terminated | May 2, 2008 | National Cancer Institute (NCI) | A more highly selected protocol with ESO TCR opened for pts with melanoma | Other (stated, no rule matched) |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | Phase 1 / Phase 2 | terminated | Jun 30, 2014 | University of California, San Francisco | FDA approved agent for this indication during enrollment | Enrollment / accrual |
| NCT02288507 | Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With… | Phase 1 | withdrawn | Nov 11, 2014 | University of Hawaii | Closed due to no accrual | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT02124850 | A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod… | Phase 1 | terminated | Apr 28, 2014 | Celgene | not stated | Not stated |
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment… | N/A | terminated | Dec 23, 2014 | Istituto Clinico Humanitas | too slow enrollment | Enrollment / accrual |
| NCT04140409 | Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation…(SCIROCCO) | Phase 4 | terminated | Oct 25, 2019 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Slow recruitment | Enrollment / accrual |
| NCT02795819 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Phase 1 | terminated | Jun 10, 2016 | Virginia Commonwealth University | Study drug no longer being clinically developed by manufacturer | Drug supply |
| NCT02030184 | Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced… | Phase 1 / Phase 2 | withdrawn | Jan 8, 2014 | University of Maryland, Baltimore | PI has left the study institution. | Other (stated, no rule matched) |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT01239342 | Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01545817 | Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma(CATChEz) | Phase 2 | terminated | Mar 7, 2012 | Novartis Pharmaceuticals | As the therapeutic landscape in renal cell carcinoma is changing, it has become apparent that… | Other (stated, no rule matched) |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With… | Phase 2 | terminated | Dec 3, 2010 | OHSU Knight Cancer Institute | low enrollment | Enrollment / accrual |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02447887 | Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma… | Phase 1 / Phase 2 | terminated | May 19, 2015 | Fox Chase Cancer Center | IRB study closure facilitated by Investigator | Investigator |
| NCT03738111 | Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma | Phase 1 | withdrawn | Nov 13, 2018 | Lee's Pharmaceutical Limited | Sponsor's commercial decision | Other (stated, no rule matched) |
| NCT01599754 | Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients(ATLAS) | Phase 3 | terminated | May 16, 2012 | SFJ Pharma Ltd. II | Primary endpoint did not reach statistical significance | Other (stated, no rule matched) |
| NCT00408252 | Efficacy of SU 011248 in Head And Neck Carcinoma | Phase 2 | terminated | Dec 6, 2006 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Too frequent grade 3-4 toxicities | Safety / toxicity |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in… | Phase 2 | terminated | Jul 3, 2013 | Women's Cancer Study Group GmbH | Early termination due to significant lack of relevant patient data for evaluation of objectives. | Other (stated, no rule matched) |
| NCT01727908 | Screening for Familial Gastric Cancer in First Degree Relatives(FamGaCan) | N/A | terminated | Nov 16, 2012 | Radboud University Medical Center | guideline developed | Other (stated, no rule matched) |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | Phase 2 | terminated | May 20, 2010 | Northwestern University | Closed due to low accrual | Enrollment / accrual |
| NCT02147301 | TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve | N/A | terminated | May 26, 2014 | University of California, San Francisco | Risk to benefit ratio is not acceptable | Other (stated, no rule matched) |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune… | N/A | terminated | Oct 18, 2016 | Vanderbilt-Ingram Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | Phase 1 / Phase 2 | withdrawn | Jun 9, 2015 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02946138 | Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of… | Phase 2 | withdrawn | Oct 27, 2016 | Shanghai Proton and Heavy Ion Center | enrollment was too slow | Enrollment / accrual |
| NCT01648465 | Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal… | Phase 2 | terminated | Jul 24, 2012 | Hellenic Cooperative Oncology Group | not stated | Not stated |
| NCT01737151 | Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk… | N/A | terminated | Nov 29, 2012 | Virginia Commonwealth University | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Jan 9, 2020source: clinicaltrials